Cavinton Forte pills 10mg N30
Condition: New product
999 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Vinpocetine
Release form
Pills
Composition
Vinpocetine 10 mg. Auxiliary substances: magnesium stearate - 2 mg, colloidal silicon dioxide - 2.5 mg, talc - 5 mg, lactose monohydrate - 83 mg, corn starch - 97.5 mg.
Pharmacological effect
A drug that improves cerebral circulation and brain metabolism. It improves brain metabolism by increasing the consumption of glucose and oxygen by the brain tissue. Increases the resistance of neurons to hypoxia, enhancing glucose transport to the brain through the BBB; translates the process of glucose decomposition into an energy-saving aerobic path; selectively blocks Ca2 + -dependent phosphodiesterase; increases levels of AMP and cGMP brain. Increases ATP concentration and ATP / AMP ratio in brain tissues; enhances the metabolism of norepinephrine and brain serotonin; stimulates the ascending branch of the noradrenergic system, has an antioxidant effect. Reduces platelet aggregation and increased blood viscosity; increases the deforming ability of erythrocytes and blocks the utilization of adenosine by erythrocytes; contributes to increased oxygen return by red blood cells. Enhances the neuroprotective effect of adenosine. Increases cerebral blood flow; reduces the resistance of cerebral vessels without significant changes in systemic blood circulation (BP, minute volume, heart rate, OPS). Not only does not have the effect of robbing, but also enhances the blood supply primarily in ischemic brain regions with low perfusion.
Pharmacokinetics
AbsorptionAfter ingestion is rapidly absorbed. Cmax in plasma is achieved 1 h after administration. Absorption occurs mainly in the proximal gastrointestinal tract. When passing through the intestinal wall is not metabolized. Cmax in the tissues is observed 2-4 hours after ingestion. Bioavailability is 7%. Distribution When repeated doses are taken at a dose of 5 mg and 10 mg, the kinetics is linear. It binds to plasma proteins by 66%. It penetrates the placental barrier. Metabolism and elimination. Clearance of 66.7 l / h exceeds the plasma volume of the liver (50 l / h), which indicates extrahepatic metabolism. T1 / 2 is 4.83 ± 1.29 h. Excreted in the urine and feces in the ratio of 3: 2.
Indications
- to reduce the severity of neurological and mental symptoms in various forms of circulatory insufficiency of the brain (including conditions after ischemic stroke, the recovery stage of hemorrhagic stroke, the consequences of a stroke, transient ischemic attack, vascular dementia, vertebrobasilar izdomas, arteriosclerosis, idiopathic heart disease, vascular dementia, atherosclerosis, idiopathology post-traumatic and hypertensive encephalopathy); - chronic vascular diseases of the eye (vascular and retinal lesions - in otorhinolaryngological practice (for the treatment of perceptual type hearing loss, Meniere's disease, idiopathic tinnitus).
Contraindications
- acute phase of hemorrhagic stroke; - severe IHD; - severe arrhythmia; - pregnancy; - lactation (breastfeeding); - children and adolescents under 18; - hypersensitivity to vinpocetine or other components of the drug.
Precautionary measures
Do not exceed recommended doses.
Use during pregnancy and lactation
Cavinton Forte is contraindicated for use during pregnancy, because Vinpocetine crosses the placental barrier. Moreover, its concentration in the placenta and in the blood of the fetus is lower than in the blood of the pregnant woman. When taken in high doses, placental bleeding and spontaneous abortions may develop, probably as a result of an increase in placental blood supply. 0.25% of the administered dose is excreted in breast milk for 1 hour. If necessary, the use of the drug during lactation should stop breastfeeding.
Dosage and administration
The duration of the course of treatment and the dose are determined individually. Inside, after eating. The average daily dose is 15-30 mg (5-10 mg 3 times / day). The initial daily dose is 15 mg. The maximum daily dose is 30 mg. The therapeutic effect develops approximately in a week from the beginning of taking the drug. It takes 3 months to achieve the full therapeutic effect. In case of disorders of the kidneys and liver, dosing regimen adjustment is not required, the absence of cumulation allows for long-term courses of treatment.
Side effects
Since the cardiovascular system: ECG changes (ST depression, prolongation of the QT interval); tachycardia, extrasystole (however, the presence of a causal relationship has not been proven, becausein the natural population, these symptoms occur with the same frequency); blood pressure lability, sensation of hot flashes. From the side of the central nervous system: sleep disturbances (insomnia, increased sleepiness), dizziness, headache, general weakness (these symptoms may be manifestations of the underlying disease), increased sweating. From the alimentary system: dry mouth, nausea, Heartburn. Allergic reactions: skin rash, urticaria.
Overdose
Currently, data on overdose of the drug Cavinton Forte are limited. Treatment: gastric lavage, taking activated charcoal, symptomatic therapy.
Interaction with other drugs
There is no interaction with simultaneous use with beta-blockers (chloranolol, pindolol), clopamide, glibenclamide, digoxin, acenocoumarol and hydrochlorothiazide, imipramine. Simultaneous use of the drug Cavinton Forte and methyldopa sometimes caused some hypotensive effect effect, sometimes an effect effect, a hypotensive effect, an effect effect, an effect effect, an effect effect, an effect effect, a methane effect, a hypotensive effect, an effect effect, an effect effect, a methyl effect, a hypotensive effect, an effect effect, a depression effect, an effect effect, a methane effect, a hypotensive effect, an effect effect, and AD. Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution while appointing K Avinton Forte with drugs of central action, antiarrhythmics and anticoagulants.
special instructions
The presence of prolonged QT syndrome and the simultaneous administration of drugs that prolong the QT interval require periodic ECG monitoring. In case of lactose intolerance, it should be noted that one tablet of Cavinton Forte contains 83 mg of lactose monohydrate. Pediatric usePreparation Cavinton Forte should not be given to children and adolescents under the age of 18 years due to insufficient data on its use in this category of patients. The effect on the ability to drive motor vehicles and control mechanisms There are no data on the effect of taking Cavinton Forte on the ability to drive and operate machinery.